Karyopharm Therapeutics (NASDAQ: KPTI) reported this afternoon that its cancer drug selinexor has passed a big test in treating some of the most desperate multiple myeloma patients-those who have failed at least five other therapies. The Newton, MA-based company will ask U.S. and European drug regulators to consider selinexor for approval.
Karyopharm (NASDAQ: KPTI) reports that selinexor has succeeded in a Phase 2B study called STORM, which tested the drug in 122 “penta-refractory” patients. According to Karyopharm, 25.4 percent of the penta-refractory patients responded to treatment with selinexor and dexamethasone, and those responses lasted a median of 4.4 months…. Read more »
UNDERWRITERS AND PARTNERS